Close Menu

NEW YORK (GenomeWeb) – Molecular diagnostics firm AltheaDx filed a preliminary prospectus on Monday with the US Securities and Exchange Commission for an initial public offering with a maximum aggregate offering price of $69 million.

The San Diego-based company has not yet priced its shares or said how many shares it plans to offer. It intends to list on the Nasdaq Global Market under ticker symbol "IDGX." Citigroup and Jefferies are the joint book-running managers on the proposed offering, and William Blair and Cantor Fitzgerald are the co-managers.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.